Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $18.33 Consensus Price Target from Brokerages
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has been assigned an average rating of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Nine ...
Hematology and Immunology Strategic Portfolio Supports Sobi's Narrow Moat
Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...